Resmetirom(Rezdiffra) is the world's first innovative drug approved for the treatment of nonalcoholic steatohepatitis (NASH), and its price, medication specifications and precautions are at the core of the concerns of patients and medical practitioners.

Resmetirom price

The pricing of Resmetirom is closely related to its specifications and production sources, and it is currently not available in China, and patients need to rely on overseas channels to obtain it.

Generic version pricing

The generic drug produced by Lucius Laos is available in three sizes: 60mg (30tablets), 80mg (30tablets), and 100mg (30tablets). Different specifications correspond to the dosage requirements, and the price difference is mainly determined by the drug content.

The current status of the innovator drug market

The original drug is produced by Madrigal Pharmaceuticals in the United States and approved by the FDA for marketing in March 2024, but it has not yet entered the domestic market and has not been included in the medical insurance, and patients need to purchase it at their own expense or obtain it through special channels.

The pricing strategy of Resmetirom reflects the value of its innovative treatment, but the high cost may limit access for some patients. In the future, the progress of domestic listing and medical insurance negotiations deserves continuous attention.

Guidance on the use of Resmetirom

Rational drug use is the key to maintaining efficacy and safety, and the plan needs to be adjusted according to the individual characteristics of patients.

Dose correlates with body weight

The recommended dose is divided according to body weight: 80mg orally per day for those weighing less than 100kg, and 100mg per day for those weighing 100kg or more. The duration of the medication is not restricted by diet, on an empty stomach or with meals.

Medication Specifications for Special Populations

Older patients do not need to adjust the dose, but they need to be monitored for adverse effects; Pregnant and lactating women need to weigh the benefits of treatment against the potential risks; Children and patients with severe liver and kidney insufficiency are contraindicated. It is contraindicated in patients with decompensated cirrhosis, and there is no need to adjust the dose in patients with mild to moderate liver impairment.

Individualized medication regimens should comprehensively consider physiological status and comorbidities, and guidelines should be strictly followed in clinical application to avoid off-label use.

Precautions for the use of Resmetirom

Drug safety involves many factors such as the management of adverse reactions, drug interactions, and storage conditions.

Management of common adverse effects

Diarrhoea, nausea, and itching are frequently reported adverse reactions, and most symptoms are mild and resolve spontaneously. If you have persistent abdominal pain or severe dizziness, you need to see a doctor to evaluate whether to stop the drug.

Storage and expiration date

Medicines should be stored at room temperature, away from high temperatures or humidity. It is valid for 24 months after opening, and should be discontinued immediately after expiration or change in character (e.g. discoloration of the tablet).

Standardized medication procedures and risk prevention and control measures can minimize the risk of treatment. The healthcare team needs to strengthen patient education to clarify medication adherence and safety.